VitreJect® Needle; OcuSafe® Needle

K230959 · Ocuject, LLC · FMI · Sep 14, 2023 · General Hospital

Device Facts

• Record ID: K230959
• Device Name: VitreJect® Needle; OcuSafe® Needle
• Applicant: Ocuject, LLC
• Product Code: FMI · General Hospital
• Decision Date: Sep 14, 2023
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 880.5570
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Vitrelect® Needle is intended for use with a luer-tip syringe for the administration of drugs. The VitreJect® Needle is indicated for intravitreal use. The OcuSafe® Needle is intended for use with a luer-tip syringe for the administration of drugs. The OcuSafe® Needle is indicated for intravitreal use.

Device Story

VitreJect® and OcuSafe® are single-lumen hypodermic needles designed for fluid injection/aspiration. VitreJect® features a spring-actuated, non-removable sliding needle cap; OcuSafe® features a removable cap. Both connect to standard luer-tip syringes. Used by healthcare professionals in clinical settings for intravitreal drug administration. Manual operation. Devices are single-use, non-toxic, non-pyrogenic, and EO-sterilized. Benefit: provides a sterile, biocompatible conduit for ophthalmic drug delivery.

Clinical Evidence

Bench testing only. No clinical data. Testing included dimensional/physical verification (ISO 7864, 80369-7), bond/material strength, needle quality (ISO 9626), particulate testing (USP <788>, <789>), and comprehensive biocompatibility (ISO 10993-1) including ocular and intravitreal irritation studies in rabbits. Results confirmed non-cytotoxic, non-sensitizing, non-irritant, non-pyrogenic, and non-hemolytic properties.

Technological Characteristics

Single-lumen needle assembly consisting of stainless steel cannula, polypropylene hub, and polypropylene cap. VitreJect® includes a stainless steel spring. Lubricated with silicone; bonded with polyacrylate. Connects to 6% luer fittings (ISO 80369-7). Sterilized via ethylene oxide (SAL 10^-6). Complies with ISO 7864, ISO 9626, and ISO 80369-7.

Indications for Use

Indicated for intravitreal administration of drugs using a luer-tip syringe by healthcare professionals in a clinical setting.

Regulatory Classification

Identification

A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set.

Predicate Devices

• SteriCap® Mini Needle and Standard Needle (K212805)

Reference Devices

• StaClear Syringe (K200242)
• Altaviz Needle Kit II (K231261)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the FDA logo is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

September 14, 2023

OcuJect, LLC % Heidi Busz Senior Regulatory Consultant Namsa 400 Highway 169 South, Suite 500 Minneapolis, Minnesota 55426

Re: K230959

Trade/Device Name: VitreJect® Needle; OcuSafe® Needle Regulation Number: 21 CFR 880.5570 Regulation Name: Hypodermic Single Lumen Needle Regulatory Class: Class II Product Code: FMI Dated: August 9, 2023 Received: August 10, 2023

Dear Heidi Busz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS)

regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

Image /page/1/Picture/6 description: The image shows the name Courtney Evans -S on the left side of the image. On the right side of the image, it says Digitally signed by Courtney Evans -S. The date is also listed as 2023.09.14 23:40:05 -04'00'.

For CAPT Alan Stevens Assistant Director DHT3C: Division of Drug Delivery and General Hospital Devices, and Human Factors OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K230959

Device Name VitreJect® Needle OcuSafe® Needle

Indications for Use (Describe)

The Vitrelect® Needle is intended for use with a luer-tip syringe for the administration of drugs. The VitreJect® Needle is indicated for intravitreal use.

The OcuSafe® Needle is intended for use with a luer-tip syringe for the administration of drugs. The OcuSafe® Needle is indicated for intravitreal use.

| Type of Use (Select one or both, as applicable) |
|-------------------------------------------------|
|-------------------------------------------------|

| <div> <span> <b> </b> </span> <span> Prescription Use (Part 21 CFR 801 Subpart D) </span> </div> |
|--------------------------------------------------------------------------------------------------------------------|
| <div> <span> </span> <span> Over-The-Counter Use (21 CFR 801 Subpart C) </span> </div> |

## CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for OcuJect LLC, a company specializing in advanced drug delivery. The logo features three interconnected hexagons in varying shades of blue on the left side. To the right of the hexagons, the company name "OcuJect" is written in a stylized, blue font, with "LLC" in smaller letters. Below the company name, the words "ADVANCED DRUG DELIVERY" are written in a smaller, sans-serif font, also in blue.

# 510(k) Summary

#### I. SUBMITTER

OcuJect, LLC 1441 Avocado Ave. Suite 204 Newport Beach, CA 92660 Phone: [phone] Email: [e-mail] Primary Contact: Leonid Lerner, MD, PhD Date prepared: September 14, 2023

II. DEVICE

Name of Device: VitreJect® / OcuSafe® Needle Common or Usual Name: Needle, Hypodermic, Single Lumen Classification name: Hypodermic Single Lumen Needle (21 CFR 880.5570) Regulatory Class: 2 Product Code: FMI

#### III. PREDICATE DEVICE

SteriCap® Mini Needle and Standard Needle, K212805 The predicate devices have not been subject to a design-related recall.

IV. REFERENCE DEVICE

StaClear Syringe, K200242 Altaviz Needle Kit II, K231261

V. DEVICE DESCRIPTION

The VitreJect® / OcuSafe® Needles are designed to provide a means of fluid injection and aspiration. The devices are single-lumen needles intended for use with a luer-tip syringe. The VitreJect® Needle has a spring-actuated, non-removable sliding cap that protects the needle prior and during its use. The OcuSafe® Needle has a removable cap that is removed prior to the needle's use. They are intended for use by health care professionals for administration of drugs. Their operation is manual. The VitreJect®/OcuSafe® Needles are single use only, non-toxic, nonpyrogenic, and sterilized by ethylene oxide gas. The VitreJect®/OcuSafe® Needles are suitable for ophthalmic use.

The VitreJect® Needle is offered in the following configurations:

| - | 30G x 5.5mm | 30G x 6mm |
|-----------|-------------|-----------|
| 31G x 4mm | 31G x 5.5mm | 31G x 6mm |
| 33G x 4mm | 33G x 5.5mm | 33G x 6mm |

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image contains the logo for OcuJect LLC Advanced Drug Delivery. The logo features three hexagons on the left side, with the top one being white, the middle one being dark blue, and the bottom one being light blue. To the right of the hexagons is the company name, "OcuJect LLC," in a stylized blue font, with the "LLC" being smaller and slightly offset. Below the company name is the tagline "ADVANCED DRUG DELIVERY" in a smaller, sans-serif blue font.

The OcuSafe® Needle is offered in the following configurations:

| - | - | 29G x 13mm |
|-----------|-----------|------------|
| - | - | 30G x 13mm |
| 31G x 4mm | - | 31G x 13mm |
| - | 33G x 8mm | - |

#### VI. INTENDED USE / INDICATIONS FOR USE

The Vitrelect® Needle is intended for use with a luer-tip syringe for the administration of drugs. The VitreJect® Needle is indicated for intravitreal use.

The OcuSafe® Needle is intended for use with a luer-tip syringe for the administration of drugs. The OcuSafe® Needle is indicated for intravitreal use.

#### VII. OF TECHNOLOGICAL CHARACTERISTICS COMPARISON WITH THE PREDICATE DEVICE

The intended use of the subject device is identical to the predicate device; designed and intended to inject fluids into, or withdraw fluids from, the body. The technological characteristics of the VitreJect® / OcuSafe® Needles are substantially equivalent to the predicate SteriCap® Mini Needle / Standard Needle (K212805). The subject device and the predicate device have identical design, material, manufacturing process, sterilization method, operation method, and packaging configuration. The OcuSafe® Needle introduces an additional configuration (31G x 4 mm) and there are minor differences in biocompatibility and performance testing and indications for use as the VitreJect® / OcuSafe® Needles are additionally indicated for intravitreal use.

A comparison of the technological characteristics between the subject and primary predicate devices is illustrated in the table below:

| Characteristic | Subject Device<br>VitreJect®/OcuSafe®<br>Needle | Predicate Device<br>SteriCap® Mini<br>Needle / Standard<br>Needle<br>(K212805) | Associated<br>Testing Standard |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant | OcuJect, LLC | Identical | - |
| Proprietary<br>Name | VitreJect®<br>OcuSafe® | SteriCap® | - |
| Product Code | FMI | Identical | - |
| Intended Use | Intended to inject fluids*<br>into, or withdraw fluids<br>from, the body. | Identical | *Namely drugs<br>Supported by<br>referenced<br>performance and<br>biocompatibility |
| Characteristic | Subject Device<br>VitreJect®/OcuSafe®<br>Needle | Predicate Device<br>SteriCap® Mini<br>Needle / Standard<br>Needle<br>(K212805) | Associated<br>Testing Standard |
| Indications | The VitreJect® Needle is intended for use with a luer-tip syringe for the administration of drugs.<br>The VitreJect® Needle is indicated for intravitreal use.<br>The OcuSafe® Needle is intended for use with a luer-tip syringe for the administration of drugs.<br>The OcuSafe® Needle is indicated for intravitreal use. | Equivalent, the predicate device does not identify specific clinical applications:<br>The SteriCap® Mini Needle and standard needles are intended for use with a luer-tip syringe (e.g. luer-lock or slip-tip luer syringe) for the administration of drugs. | testing<br>ISO 10993-1,<br>ISO 10993-7,<br>ISO 10993-10,<br>USP <788>,<br>USP <789> |
| Intended Users<br>and Environment | Health care professionals in a clinical setting | Identical | - |
| Principle of<br>Operation | Connects to a luer type syringe to serve as a conduit for the manual advancement and withdrawal of fluid | Identical | ISO 80369-7,<br>ISO 7864,<br>ISO 9626 |
| Functional<br>Construct | Single lumen needle | Identical | ISO 7864,<br>ISO 9626 |
| Design/<br>Construction | Needle Assembly:<br>Cannula, needle hub, needle cap (spring loaded or removable)<br>Designed to fit standard 6% luer fittings | Identical | ISO 80369-7,<br>ISO 7864,<br>ISO 9626 |
| Device<br>Components and<br>Materials | Cannula: stainless steel<br>Lubricant: silicone<br>Adhesive: polyacrylate<br>Needle Cap: polypropylene<br>Hub: polypropylene<br>Spring (VitreJect®):<br>stainless steel | Identical<br>Stainless steel spring in SteriCap® model only | ISO 10993-1,<br>ISO 10993-2,<br>ISO 10993-4,<br>ASTM F756,<br>ISO 10993-5,<br>ISO 10993-7,<br>ISO 10993-10,<br>ISO 10993-11,<br>ISO 10993-12,<br>ISO 10993-17, |
| Characteristic | Subject Device<br>VitreJect®/OcuSafe®<br>Needle | Predicate Device<br>SteriCap® Mini<br>Needle / Standard<br>Needle<br>(K212805) | Associated<br>Testing Standard |
| Needle Length<br>(Exposed) | VitreJect®:<br>4 mm / 5.5 mm / 6 mm<br>OcuSafe®:<br>13 mm<br>8 mm<br>4 mm | Equivalent, the<br>predicate Standard<br>Needle is not offered<br>in 4 mm:<br><br>SteriCap®:<br>4 mm / 5.5 mm / 6 mm<br>Standard:<br>13 mm / 8 mm | ISO 7864,<br>ISO 9626 |
| Needle Gauge | VitreJect®: 30G, 31G and<br>33G.<br>OcuSafe®: 29G, 30G, 31G<br>and 33G. | Identical<br>SteriCap®: 30G, 31G<br>and 33G.<br>Standard Needle:<br>29G, 30G, 31G and<br>33G. | ISO 7864,<br>ISO 9626 |
| Cannula tip<br>configuration | Lancet bevel | Identical | ISO 7864,<br>ISO 9626 |
| Sterilization and<br>Shelf Life | Provided Sterile,<br>Single-Use<br>100 individual blister-packed<br>devices packaged into a shelf<br>carton<br>Sterilization Method: EO<br>SAL: 10-6<br>Shelf Life: 5 years<br><br>Ethylene oxide residual were<br>assessed per ISO 10993-7.<br>Endotoxins were tested as<br>recommended in FDA<br>guidance Endotoxin Testing<br>Recommendations for<br>Single-Use Intraocular<br>Ophthalmic Devices. | Identical<br>Reduced residual and<br>endotoxin limits for<br>ophthalmic use not<br>applicable. | AAMI TIR28,<br>ISO 11135-1,<br>ISO 10993-7,<br>USP <85>,<br>USP <161>,<br>ANSI/AAMI<br>ST72,<br>ASTM F1980-16,<br>ISO 7864,<br>ISO 9626,<br>ISO 80369-7,<br>ASTM F88/F88-<br>15,<br>ASTM F1929-15,<br>ASTM D4169-16 |
| Characteristic | Subject Device<br>VitreJect®/OcuSafe®<br>Needle | Predicate Device<br>SteriCap® Mini<br>Needle / Standard<br>Needle<br>(K212805) | Associated<br>Testing Standard |
| Biocompatibility<br>per ISO 10993-1 | Non-cytotoxic | Identical | ISO 10993-5 |
| | Non-sensitizer | Identical | ISO 10993-10 |
| | Non-irritant, Intracutaneous | Identical | ISO 10993-23 |
| | Non-irritant, Ocular | Equivalent, Ocular, | ISO 10993-10 |
| | Non-irritant, Intravitreal<br>Injection | Intravitreal Injection<br>and Intraocular | ISO 13485 |
| | Non-irritant, Intraocular | Irritation testing not<br>performed on the<br>predicate device. | ISO 13485 |
| | Non-pyrogenic | Identical | USP <151>, ISO<br>10993-11 |
| | Non-toxic | Identical | ISO 10993-11 |
| | Non-hemolytic | Identical | ISO 10993-4,<br>ASTM F756<br>ISO 10993-3 |

Page 2 Traditional 510(k)

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the logo for OcuJect LLC, a company specializing in advanced drug delivery. The logo features three hexagons of different shades of blue on the left side. To the right of the hexagons is the company name, "OcuJect LLC", in a stylized blue font. Below the company name is the tagline "ADVANCED DRUG DELIVERY" in a smaller, sans-serif blue font.

OcuJect, LLC
VitreJect® / OcuSafe® Needle

Page 3 Page 3
Traditional 510(k)

{6}------------------------------------------------

Image /page/6/Picture/0 description: The image shows the logo for OcuJect LLC. The logo features three hexagons on the left side, with the top one being white, the middle one being dark blue, and the bottom one being light blue. To the right of the hexagons is the company name "OcuJect LLC" in a stylized blue font, with the "LLC" being smaller and slightly offset. Below the company name is the text "ADVANCED DRUG DELIVERY" in a smaller, sans-serif blue font.

{7}------------------------------------------------

Image /page/7/Picture/0 description: The image shows the logo for OcuJect LLC. The logo features three hexagons on the left side, with the top one being white, the middle one being dark blue, and the bottom one being light blue. To the right of the hexagons is the company name, "OcuJect LLC", in a stylized blue font, with the "LLC" being smaller and slightly offset. Below the company name is the text "ADVANCED DRUG DELIVERY" in a smaller, sans-serif blue font.

#### VIII. PERFORMANCE DATA

The following non-clinical testing was performed to confirm the safety and effectiveness of the VitreJect® and OcuSafe® Needles compared to the predicate devices. Performance testing was performed as per the design control system. The following tests were conducted:

- Dimensional and Physical Properties Verification ●
- o ISO 7864, ISO 80369-7
- . Bond and Material Strength Verification
- o ISO 7864, ISO 80369-7
- Needle quality
- o ISO 9626, ISO 7864
- Color coding

●

- o ISO 6009, ISO 7864
- Luer connector
- o ISO 80369-7
- Particulate testing
- o USP <788>, USP <789>
- Biocompatibility (ISO 10993-1) ●

VitreJect® and OcuSafe® Needles are categorized as externally communicating devices with limited (<24 hours) direct tissue and indirect blood/tissue path contact. OcuJect, LLC

{8}------------------------------------------------

Image /page/8/Picture/0 description: The image is a logo for OcuJect LLC, a company specializing in advanced drug delivery. The logo features three interlocking hexagons in different shades of blue on the left side. To the right of the hexagons is the company name, "OcuJect LLC," in a modern, sans-serif font, with "LLC" in a smaller font size. Below the company name is the tagline "ADVANCED DRUG DELIVERY" in a similar font, emphasizing the company's focus.

completed the following biological safety tests:

- Cytotoxicity о
- Sensitization O
- Irritation, Intracutaneous O
- Irritation, Ocular O
- Irritation, Intravitreal Injection O
- Irritation, Intraocular O
- Acute Systemic Toxicity O
- Pyrogenicity o
- Hemolysis O

The test article extracts showed no evidence of cvtotoxic effect, were not considered a sensitizer, showed no evidence of erythema and edema, were not considered an irritant to the ocular tissue of the rabbit, were not considered inflammatory to intraocular tissues of the rabbit, were not considered an irritant to the intraocular tissues of the rabbit, did not show evidence of systemic toxicity, were not considered pyrogenic, and were not considered hemolytic. The biological safety testing demonstrates the subject device is biocompatible for its intended use.

### IX. SUBSTANTIAL EQUIVALENCE

The Vitrelect® and OcuSafe® Needles are substantially equivalent to the predicate device when evaluating intended use and technological characteristics.

- The subject device has the identical intended use as the predicate device. The subject device is additionally indicated for intravitreal use.
- The subject device and predicate device are substantially equivalent with only minor technological differences in configuration/size offering, biocompatibility and performance testing.
- . To support intravitreal use, the subject device was tested for compliance with intraocular requirements for ethylene oxide residuals, endotoxin, particulate matter according to USP <789> (using both the light obscuration and microscopy test methods), and intraocular irritation testing and passed.
- Biocompatibility testing and performance testing demonstrate the additional configuration/size offering and additional indication do not raise new or different questions of safety and effectiveness.

The biocompatibility testing data and particulate test data in conjunction with the performance test data demonstrating compliance with ISO 7864, ISO 9626, and ISO 80369-7 demonstrate that the VitreJect® and OcuSafe® Needles meet the established safety and performance characteristics of the device and demonstrate substantial equivalence.

### X. CONCLUSIONS

The VitreJect® and OcuSafe® Needles met the established safety and performance characteristics

{9}------------------------------------------------

Image /page/9/Picture/0 description: The image shows the logo for OcuJect LLC, a company specializing in advanced drug delivery. The logo features three hexagons of varying shades of blue on the left side. To the right of the hexagons is the company name, "OcuJect LLC," in a stylized blue font. Below the company name is the tagline "ADVANCED DRUG DELIVERY," also in blue.

for a hypodermic single-lumen needle. Suitability of the subject devices for the additional configuration/size offering and additional indication of intravitreal use was evaluated through biocompatibility and performance testing. These differences do not raise any new or different questions of safety or effectiveness. Testing demonstrates the VitreJect® and OcuSafe® Needles are as safe and effective as the predicate device and will perform as intended.

The Vitrelect® and OcuSafe® Needles are biocompatible for the intended use and demonstrate equivalent performance to the predicate device. The VitreJect® and OcuSafe® Needles are substantially equivalent to the SteriCap® Mini Needle and Standard Needles cleared under K212805.